ALCSI Podcast: Dr. Bruce Johnson
from The American Lung Cancer Screening Initiative Podcast Hosted by American Lung Cancer Screening Initiative
On this ALCSI podcast, Dr. Bruce Johnson talks about his translational research related to testing the efficacy of novel therapeutic agents against lung cancer with specific genomic changes. He also discusses issues around equity in lung cancer screening and treatment. Dr. Johnson received his MD from the University of Minnesota in 1979 and his postgraduate training at the University of Chicago and the National Cancer Institute. After serving at NCI, where he most recently headed the Lung Cancer Biology Section, he joined DFCI in 1999. He currently co-leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program. Dr. Johnson was previously the Chief Clinical Research Officer at the Dana-Farber Cancer Institute, and is now a Senior Consultant on the Executive Leadership Team. Lung cancer is the leading cause of cancer death in the world. Large clinical trials have shown that lung cancer screening through low-dose computed tomography (CT) reduces lung cancer mortality by up to 33%. In fact, if every high-risk American were to get screened right now, thousands of lives could be saved this year alone. However, less than 6% of high-risk Americans are currently getting screened. Visit our website at https://www.alcsi.org/ for free educational resources and webinars on lung cancer and lung cancer screening.
Embed this episode
No transcript yet.